L3VLUP
ProSign in

ADAPY in the 13F filings

Adaptimmune Therapeutics ADR · CUSIP 00653A107

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022
Quarter end
30 Jun 2022
the date the book describes
Filed
8 Aug 2022
up to 45 days after the quarter end
Managers listing it
1
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q1 2022 and Q2 2022; 1 listed it in both
Shares listed
15,321,346
combined, among listed positions
Reported value
$26m
combined, at the quarter end

Managers listing ADAPY in Q2 2022

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q1 2022, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

1 of 1 holder

ActionFiling
Baillie Gifford & Co15,321,346$26munder 0.1%Trimmed-59,1928 Aug 2022 (the filing on sec.gov)

Largest increases and reductions, by shares

Q1 2022 to Q2 2022, among managers that listed it in both quarters or opened it.

Increases

No increase among listed positions.

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
1 in Q1 2023 to 1 in Q4 2024

Tracked managers listing it, at least.

01234201620172018201920202021202220232024
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
ADAPY by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20152$25mn.a.n.a.
Q3 20151$21mn.a.n.a.
Q4 20151$55mn.a.n.a.
Q1 20162$41mn.a.n.a.
Q2 20162$41mn.a.n.a.
Q3 20162$39mn.a.n.a.
Q4 20162$22mn.a.n.a.
Q1 20172$43mn.a.n.a.
Q2 20172$36mn.a.n.a.
Q3 20172$67mn.a.n.a.
Q4 20172$58mn.a.n.a.
Q1 20182$105mn.a.n.a.
Q2 20183$131mn.a.n.a.
Q3 20183$152mn.a.n.a.
Q4 20182$60mn.a.n.a.
Q1 20192$46mn.a.n.a.
Q2 20192$44mn.a.n.a.
Q3 20192$17mn.a.n.a.
Q4 20192$13mn.a.n.a.
Q1 20202$34mn.a.n.a.
Q2 20204$159mn.a.n.a.
Q3 20203$140mn.a.n.a.
Q4 20203$108mn.a.n.a.
Q1 20213$114mn.a.n.a.
Q2 20213$93mn.a.n.a.
Q3 20212$108mn.a.n.a.
Q4 20211$52mn.a.n.a.
Q1 20221$32mn.a.n.a.
Q2 20221$26mn.a.n.a.
Q3 20221$16mn.a.n.a.
Q4 20222$25mn.a.n.a.
Q1 20231$19mn.a.n.a.
Q2 20231$16mn.a.n.a.
Q3 20231$13mn.a.n.a.
Q4 20231$13m01
Q1 20241$25m01
Q2 20241$15m01
Q3 20241$16m10
Q4 20241$6.4m01

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

ADAPY and GILD →ADAPY and AMGN →ADAPY and ARGX →Choose a stock to compare with ADAPY →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own ADAPY, latest filings →Back to the 13F Explorer →